Seelos therapeutics to present a poster on sls-004 at the 11th annual alzheimer's & parkinson's drug development summit

- seelos recently released in vivo gene therapy data of sls-004 utilizing crispr-dcas9 in parkinson's disease demonstrating downregulation of alpha synuclein and recovery of tyrosine hydroxylase-positive (th+) dopaminergic neurons. new york , feb. 10, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster on sls-004 at the 11th annual alzheimer's & parkinson's drug development summit in san francisco, ca, february 21-23, 2023.
SEEL Ratings Summary
SEEL Quant Ranking